This Article Full Text Full Text (PDF) All Versions of this Article: 109/7/861    most recent 01.CIR.0000116752.12261.D4v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chaves, A. J. Articles by Sousa, J. E. Search for Related Content PubMed PubMed Citation Articles by Chaves, A. J. Articles by Sousa, J. E. Related Collections Restenosis Type 2 diabetes Catheter-based coronary interventions: stents Coronary imaging: angiography/ultrasound/Doppler/CC

(Circulation. 2004;109:861-866.)
© 2004 American Heart Association, Inc.

Clinical Investigation and Reports

Volumetric Analysis of In-Stent Intimal Hyperplasia in Diabetic Patients Treated With or Without Abciximab

Results of the Diabetes Abciximab steNT Evaluation (DANTE) Randomized Trial

Áurea J. Chaves, MD; Amanda G.M.R. Sousa, MD, PhD; Luiz A. Mattos, MD, PhD; Alexandre Abizaid, MD, PhD; Rodolfo Staico, MD; Fausto Feres, MD, PhD; Marinella Centemero, MD; Luiz F. Tanajura, MD; Andrea Abizaid, MD, PhD; Ibraim Pinto, MD, PhD; Galo Maldonado, MD; Ana Seixas, MD; Marco A. Costa, MD, PhD; Ângela Paes, MSc; Gary S. Mintz, MD; J. Eduardo Sousa, MD, PhD

From Instituto "Dante Pazzanese" de Cardiologia, São Paulo, Brazil; and the Cardiovascular Research Foundation (G.S.M.), New York, NY.

Correspondence to Prof J. Eduardo Sousa, Instituto "Dante Pazzanese" de Cardiologia, Av. Dr. Dante Pazzanese, 500-04012180, São Paulo, Brazil. E-mail jesousa{at}uol.com.br

Received September 12, 2003; revision received November 9, 2003; accepted November 25, 2003.

Background— In diabetic patients in the Evaluation of Platelet IIb/IIIa Inhibitor for Stenting (EPISTENT) trial, abciximab reduced target vessel revascularization by 50% compared with placebo. Whether this is a result of a lower restenosis rate caused by inhibition of intimal hyperplasia remains to be defined.

Methods and Results— The purpose of this study was to determine whether abciximab at the time of stent implantation would reduce in-stent intimal hyperplasia measured by intravascular ultrasound at 6-month follow-up in type 2 diabetics. Ninety-six diabetic patients (96 lesions) who underwent elective stent implantation for a de novo lesion in a native coronary artery were randomly assigned to receive abciximab or no abciximab. In-stent intimal hyperplasia volume, expressed as percentage of stent volume, did not differ between groups: 41.3±21.0% for those treated with abciximab versus 40.5±18.3% for those treated without abciximab (P=0.9). There were also no significant differences in angiographic minimal luminal diameter at follow-up (1.74±0.69 versus 1.66±0.63 mm; P=0.5), late loss (1.03±0.63 versus 1.07±0.58 mm; P=0.7), restenosis rate (17.8% versus 22.9%; P=0.5), or cumulative incidence of major adverse cardiac events at 12 months (19.1% versus 20.4%; P=0.9).

Conclusions— Six-month intravascular ultrasound volumetric analysis showed that abciximab, at the time of coronary stent implantation, was not associated with a reduction of in-stent intimal hyperplasia in diabetic patients.

Key Words: diabetes mellitus • stents • glycoproteins • ultrasonics

This article has been cited by other articles:

				E. Raichlin, J.-H. Bae, S. S. Kushwaha, R. J. Lennon, A. Prasad, C. S. Rihal, and A. Lerman Inflammatory Burden of Cardiac Allograft Coronary Atherosclerotic Plaque Is Associated With Early Recurrent Cellular Rejection and Predicts a Higher Risk of Vasculopathy Progression J. Am. Coll. Cardiol., April 14, 2009; 53(15): 1279 - 1286. [Abstract] [Full Text] [PDF]

				E. Raichlin, J.-H. Bae, Z. Khalpey, B. S. Edwards, W. K. Kremers, A. L. Clavell, R. J. Rodeheffer, R. P. Frantz, C. Rihal, A. Lerman, et al. Conversion to Sirolimus as Primary Immunosuppression Attenuates the Progression of Allograft Vasculopathy After Cardiac Transplantation Circulation, December 4, 2007; 116(23): 2726 - 2733. [Abstract] [Full Text] [PDF]

				S. Lavi, J. P. McConnell, C. S. Rihal, A. Prasad, V. Mathew, L. O. Lerman, and A. Lerman Local Production of Lipoprotein-Associated Phospholipase A2 and Lysophosphatidylcholine in the Coronary Circulation: Association With Early Coronary Atherosclerosis and Endothelial Dysfunction in Humans Circulation, May 29, 2007; 115(21): 2715 - 2721. [Abstract] [Full Text] [PDF]

				H. S. Gurm, I. J. Sarembock, D. J. Kereiakes, J. J. Young, R. A. Harrington, N. Kleiman, F. Feit, K. Wolski, J. A. Bittl, R. Wilcox, et al. Use of Bivalirudin During Percutaneous Coronary Intervention in Patients With Diabetes Mellitus: An Analysis From the Randomized Evaluation in Percutaneous Coronary Intervention Linking Angiomax to Reduced Clinical Events (REPLACE)-2 Trial J. Am. Coll. Cardiol., June 21, 2005; 45(12): 1932 - 1938. [Abstract] [Full Text] [PDF]

				A. J. Chaves, A. G.M.R. Sousa, J. W. Eikelboom, J. M. Rankin, A. Kastrati, J. Mehilli, H. Schuhlen, A. Dibra, J. Pache, A. Schomig, et al. Letters Regarding Article by Mehilli et al, "Randomized Clinical Trial of Abciximab in Diabetic Patients Undergoing Elective Percutaneous Coronary Interventions After Treatment With a High Loading Dose of Clopidogrel" * Response Circulation, May 31, 2005; 111(21): e370 - e371. [Full Text] [PDF]

				J. Mehilli, A. Kastrati, H. Schuhlen, A. Dibra, F. Dotzer, N. von Beckerath, H. Bollwein, J. Pache, J. Dirschinger, P. P. Berger, et al. Randomized Clinical Trial of Abciximab in Diabetic Patients Undergoing Elective Percutaneous Coronary Interventions After Treatment With a High Loading Dose of Clopidogrel Circulation, December 14, 2004; 110(24): 3627 - 3635. [Abstract] [Full Text] [PDF]